

February 13, 2019

Listing Department
BSE LIMITED
P J Towers, Dalal Street, Fort,
Mumbai-400 001

Code: 532 321

Listing Department
NATIONAL STOCK EXCHANGE OF INDIA LIMITED
Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai-400 051

Code: CADILAHC

Re.: Press Release.

Dear Sir / Madam,

Please find enclosed a copy of press release dated February 13, 2019 titled "Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Capsules USP".

The contents of the press release give full details.


Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For, **CADILA HEALTHCARE LIMITED**



DHAVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus receives final approval from the USFDA for Triamterene and Hydrochlorothiazide Capsules USP

Ahmedabad, 13 February, 2019

Zydus Cadila has received the final approval from the USFDA to market Triamterene and Hydrochlorothiazide Capsules USP (US RLD – DYAZIDE®), 37.5 mg/25 mg. It will be manufactured at the group's formulations manufacturing facility at SEZ, Ahmedabad.

The fixed dose combination of Triamterene and Hydrochlorothiazide is indicated for the treatment of hypertension or edema in patients who have developed hypokalemia (low serum potassium levels) on Hydrochlorothiazide alone. It is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. This medication may be used alone or as an adjunct to other antihypertensive drugs.

The group now has 249 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.
